BACKGROUND AND AIMS: Radiofrequency-ablation (RFA) is increasingly used for destruction of unresectable primary and secondary liver tumors. We report our experience in the use of RFA for the management of unresectable hepatic malignancies. PATIENTS AND METHODS: Between February 2000 and December 2004 we have undertaken 120 RFA procedures to ablate 426 unresectable primary or metastatic liver tumors in 88 patients. RFA was performed via laparotomy (n=68), laparoscopy (n=9) or a percutaneous approach (n=43). Primary liver cancer was treated in seven patients (8%) and metastatic liver tumors were treated in 81 patients (92%). All patients were followed to assess complications, treatment response and recurrence of malignant disease. RESULTS: Procedure-related complication rate was low (3.4%). During a mean follow-up of 21.2 months, 15 patients had local tumor progression (17%), 21 patients (23.9%) had new malignant disease and 27 patients (30.7%) died from intervention-unrelated complications of their malignant disease. Additional liver lesions were identified in 27 (35%) of 77 cases by intraoperative ultrasound. Thirty-six patients received simultaneous resection and RFA. CONCLUSION: RFA is a safe, well-tolerated and effective treatment for patients with unresectable primary and secondary liver malignancies.
BACKGROUND AND AIMS: Radiofrequency-ablation (RFA) is increasingly used for destruction of unresectable primary and secondary liver tumors. We report our experience in the use of RFA for the management of unresectable hepatic malignancies. PATIENTS AND METHODS: Between February 2000 and December 2004 we have undertaken 120 RFA procedures to ablate 426 unresectable primary or metastatic liver tumors in 88 patients. RFA was performed via laparotomy (n=68), laparoscopy (n=9) or a percutaneous approach (n=43). Primary liver cancer was treated in seven patients (8%) and metastatic liver tumors were treated in 81 patients (92%). All patients were followed to assess complications, treatment response and recurrence of malignant disease. RESULTS: Procedure-related complication rate was low (3.4%). During a mean follow-up of 21.2 months, 15 patients had local tumor progression (17%), 21 patients (23.9%) had new malignant disease and 27 patients (30.7%) died from intervention-unrelated complications of their malignant disease. Additional liver lesions were identified in 27 (35%) of 77 cases by intraoperative ultrasound. Thirty-six patients received simultaneous resection and RFA. CONCLUSION: RFA is a safe, well-tolerated and effective treatment for patients with unresectable primary and secondary liver malignancies.
Authors: S A Curley; F Izzo; P Delrio; L M Ellis; J Granchi; P Vallone; F Fiore; S Pignata; B Daniele; F Cremona Journal: Ann Surg Date: 1999-07 Impact factor: 12.969
Authors: Steven A Curley; Paolo Marra; Karen Beaty; Lee M Ellis; J Nicolas Vauthey; Eddie K Abdalla; Courtney Scaife; Chan Raut; Robert Wolff; Haesun Choi; Evelyne Loyer; Paolo Vallone; Francesco Fiore; Fabrizio Scordino; Vincenzo De Rosa; Raffaele Orlando; Sandro Pignata; Bruno Daniele; Francesco Izzo Journal: Ann Surg Date: 2004-04 Impact factor: 12.969
Authors: John L Nosher; Inaya Ahmed; Akshar N Patel; Vyacheslav Gendel; Philip G Murillo; Rebecca Moss; Salma K Jabbour Journal: J Gastrointest Oncol Date: 2015-04
Authors: Simon S Lo; Susan D Moffatt-Bruce; Laura A Dawson; Roderich E Schwarz; Bin S Teh; Nina A Mayr; Jiade J Lu; John C Grecula; Thomas E Olencki; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2011-05-24 Impact factor: 66.675
Authors: Constantinos T Sofocleous; Sandeep Garg; Lydia M Petrovic; Mithat Gonen; Elena N Petre; David S Klimstra; Stephen B Solomon; Karen T Brown; Lynn A Brody; Ann M Covey; Ronald P Dematteo; Lawrence Schwartz; Nancy E Kemeny Journal: Ann Surg Oncol Date: 2012-07-03 Impact factor: 5.344
Authors: Sergio A Dromi; Meghaan P Walsh; Sarah Herby; Bryan Traughber; Jianwu Xie; Karun V Sharma; Kiran P Sekhar; Alfred Luk; David J Liewehr; Matthew R Dreher; Terry J Fry; Bradford J Wood Journal: Radiology Date: 2009-02-27 Impact factor: 11.105
Authors: Klaas M Govaert; Charlotte S van Kessel; Martijn Lolkema; Theo J M Ruers; Inne H M Borel Rinkes Journal: Curr Colorectal Cancer Rep Date: 2012-03-17